Galapagos Competitors and Similar CompaniesClear all

Galapagos's competitors and similar companies include Roivant Sciences, Pliant Therapeutics, TheraIndx and CanSino Biologics.

	Galapagos Galapagos is a biotechnology company.	Roivant Sciences Roivant Sciences is a company that develops and commercializes medicines.	Pliant Therapeutics Pliant Therapeutics is a company focused on discovering, developing, and commercializing treatments for fibrotic diseases.	TheraIndx TheraIndx is a company that provides integrated drug discovery services.	CanSino Biologics CanSino Biologics (康希诺生物股份公司) is a biopharmaceutical company that provides solutions for the prevention and treatment of infectious diseases.
Founding Date	Founding Date 1999	Founding Date 2014	Founding Date 2016	Founding Date 2014	Founding Date 2009
Type	Type Public	Type Public	Type Private	Type Private	Type Public
Tags	Tags Healthcare Technology biotech clinical research drug development	Tags Healthcare biotech drug development healthtech pharma	Tags Healthcare healthtech pharma therapy	Tags Healthcare biotech clinical research drug development	Tags Healthcare biotech clinical research drug development
Locations	Locations Mechelen, BE HQ Romainville, FR Leiden, NL Basel, CH Waltham, US	Locations London, GB HQ Basel, CH Boston, US New York, US	Locations South San Francisco, US HQ	Locations Indiranagara, IN HQ	Locations Tianjin, CN HQ
Employees	Employees 70437% decrease	Employees 908	Employees 1519% decrease	Employees 244% decrease	Employees 1,10526% decrease
Valuation ($)	Valuation ($) 2 b	Valuation ($) 8.8 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) €1.1b (FY, 2025)	Revenue (est.) $8.3m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥1.1b (FY, 2025)
Cost of goods	Cost of goods €25.7m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥81.4m (FY, 2025)
Gross profit	Gross profit €1.2b (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ¥1.1b (FY, 2025)
Net income	Net income €320.9m (FY, 2025)	Net income ($397.9m) (FY, 2025)	Net income N/A	Net income N/A	Net income ¥27.9m (FY, 2025)
Funding
Total funding raised	Total funding raised $ 3.7m	Total funding raised $ 1.9b	Total funding raised $ 107m	Total funding raised N/A	Total funding raised $ 76m